JP2008520742A5 - - Google Patents

Download PDF

Info

Publication number: JP2008520742A5
Authority: JP; Japan
Prior art keywords: group; compound; halogen; optionally substituted; alkyl
Prior art date: 2005-11-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2007543450A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008520742A (ja

Filing date

2005-11-23

Publication date

2009-03-05

2005-11-23 Application filed filed Critical

2005-11-23 Priority claimed from PCT/US2005/042484 external-priority patent/WO2006058088A2/en

2008-06-19 Publication of JP2008520742A publication Critical patent/JP2008520742A/ja

2009-03-05 Publication of JP2008520742A5 publication Critical patent/JP2008520742A5/ja

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims 62
229910052736 halogen Inorganic materials 0.000 claims 44
150000002367 halogens Chemical group 0.000 claims 44
125000003118 aryl group Chemical group 0.000 claims 37
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 27
229910052739 hydrogen Inorganic materials 0.000 claims 24
239000001257 hydrogen Substances 0.000 claims 24
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 22
150000003839 salts Chemical class 0.000 claims 20
239000012453 solvate Substances 0.000 claims 20
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 11
125000001624 naphthyl group Chemical group 0.000 claims 8
230000033115 angiogenesis Effects 0.000 claims 6
230000006711 vascular endothelial growth factor production Effects 0.000 claims 6
201000010099 disease Diseases 0.000 claims 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
125000003545 alkoxy group Chemical group 0.000 claims 4
201000001320 Atherosclerosis Diseases 0.000 claims 3
206010028980 Neoplasm Diseases 0.000 claims 3
208000008589 Obesity Diseases 0.000 claims 3
201000004681 Psoriasis Diseases 0.000 claims 3
229910052794 bromium Inorganic materials 0.000 claims 3
201000011510 cancer Diseases 0.000 claims 3
229910052801 chlorine Inorganic materials 0.000 claims 3
239000000460 chlorine Substances 0.000 claims 3
208000037976 chronic inflammation Diseases 0.000 claims 3
230000006020 chronic inflammation Effects 0.000 claims 3
125000000753 cycloalkyl group Chemical group 0.000 claims 3
239000003814 drug Substances 0.000 claims 3
208000026278 immune system disease Diseases 0.000 claims 3
208000027866 inflammatory disease Diseases 0.000 claims 3
208000023589 ischemic disease Diseases 0.000 claims 3
208000002780 macular degeneration Diseases 0.000 claims 3
230000003211 malignant effect Effects 0.000 claims 3
238000004519 manufacturing process Methods 0.000 claims 3
235000020824 obesity Nutrition 0.000 claims 3
239000008194 pharmaceutical composition Substances 0.000 claims 3
125000000168 pyrrolyl group Chemical group 0.000 claims 3
206010039073 rheumatoid arthritis Diseases 0.000 claims 3
206010012689 Diabetic retinopathy Diseases 0.000 claims 2
125000000217 alkyl group Chemical group 0.000 claims 2
150000001412 amines Chemical class 0.000 claims 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
125000001072 heteroaryl group Chemical group 0.000 claims 2
150000002431 hydrogen Chemical group 0.000 claims 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
125000004076 pyridyl group Chemical group 0.000 claims 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
208000017442 Retinal disease Diseases 0.000 claims 1
206010038923 Retinopathy Diseases 0.000 claims 1
125000003277 amino group Chemical group 0.000 claims 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
239000003623 enhancer Substances 0.000 claims 1
229910052731 fluorine Inorganic materials 0.000 claims 1
125000005843 halogen group Chemical group 0.000 claims 1
150000004677 hydrates Chemical class 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
230000000302 ischemic effect Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
0 *N(CC1)c2c1c1cc(I)ccc1[n]2* Chemical compound *N(CC1)c2c1c1cc(I)ccc1[n]2* 0.000 description 1

JP2007543450A 2004-11-23 2005-11-23 Ｖｅｇｆ産生の阻害に有用なカルバゾール誘導体、カルボリン誘導体およびインドール誘導体 Pending JP2008520742A (ja)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US62988904P	2004-11-23	2004-11-23
US63373804P	2004-12-06	2004-12-06
US63928304P	2004-12-27	2004-12-27
PCT/US2005/042484 WO2006058088A2 (en)	2004-11-23	2005-11-23	Carbazole, carboline and indole derivatives useful in the inhibition of vegf production

Publications (2)

Publication Number	Publication Date
JP2008520742A JP2008520742A (ja)	2008-06-19
JP2008520742A5 true JP2008520742A5 (2)	2009-03-05

Family

ID=36143248

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2007543448A Pending JP2008520740A (ja)	2004-11-23	2005-11-23	Ｖｅｇｆ産生を阻害する活性因子としての置換されたフェノール
JP2007543450A Pending JP2008520742A (ja)	2004-11-23	2005-11-23	Ｖｅｇｆ産生の阻害に有用なカルバゾール誘導体、カルボリン誘導体およびインドール誘導体
JP2007543449A Pending JP2008520741A (ja)	2004-11-23	2005-11-23	翻訳制御によるｖｅｇｆ生成を阻害するための活性因子としてのテトラヒドロカルバゾール

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
JP2007543448A Pending JP2008520740A (ja)	2004-11-23	2005-11-23	Ｖｅｇｆ産生を阻害する活性因子としての置換されたフェノール

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2007543449A Pending JP2008520741A (ja)	2004-11-23	2005-11-23	翻訳制御によるｖｅｇｆ生成を阻害するための活性因子としてのテトラヒドロカルバゾール

Country Status (6)

Country	Link
US (3)	US8946444B2 (2)
EP (3)	EP1824821A2 (2)
JP (3)	JP2008520740A (2)
CA (3)	CA2588389A1 (2)
MX (3)	MX2007006180A (2)
WO (3)	WO2006058088A2 (2)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10252667A1 (de)	2002-11-11	2004-05-27	Grünenthal GmbH	Spirocyclische Cyclohexan-Derivate
US7767689B2 (en)	2004-03-15	2010-08-03	Ptc Therapeutics, Inc.	Carboline derivatives useful in the treatment of cancer
UA92317C2 (ru)	2004-03-15	2010-10-25	Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК.	Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US8076352B2 (en)	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en)	2004-03-15	2011-12-13	Ptc Therapeutics, Inc.	Inhibition of VEGF translation
EP1831225A2 (en)	2004-11-19	2007-09-12	The Regents of the University of California	Anti-inflammatory pyrazolopyrimidines
DE102005016460A1 (de) *	2005-04-11	2006-10-19	Grünenthal GmbH	Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
CA2612723A1 (en)	2005-06-24	2007-01-04	Eli Lilly And Company	Tetrahydrocarbazole derivatives useful as androgen receptor modulators
US20070149557A1 (en) *	2005-11-21	2007-06-28	Amgen Inc.	CXCR3 antagonists
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2007114926A2 (en)	2006-04-04	2007-10-11	The Regents Of The University Of California	Kinase antagonists
CA2656357C (en)	2006-07-19	2014-05-06	E.I. Du Pont De Nemours And Company	Process for making 3-substituted 2-amino-5-halobenzamides
ITMI20061581A1 (it) *	2006-08-04	2008-02-05	Univ Bari	Ligandi del recettore beta-3 adrenergico e loro uso in terapia
UA98777C2 (en)	2006-11-20	2012-06-25	Эли Лилли Энд Компани	Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
DE102007009235A1 (de) *	2007-02-22	2008-09-18	Grünenthal GmbH	Spirocyclische Cyclohexan-Derivate
EP2215074B1 (en) *	2007-09-27	2014-02-19	The United States of America, as Represented by the Secretary, Department of Health and Human Services	Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
WO2009078423A1 (ja) *	2007-12-18	2009-06-25	National University Corporation University Of Toyama	アルドース還元酵素阻害活性を有する縮合三環化合物
MX2010007419A (es)	2008-01-04	2010-11-12	Intellikine Inc	Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2252293B1 (en)	2008-03-14	2018-06-27	Intellikine, LLC	Kinase inhibitors and methods of use
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
ATE537143T1 (de)	2008-03-27	2011-12-15	Gruenenthal Gmbh	Spiro(5.5)undecan derivate
PT2260042E (pt)	2008-03-27	2011-12-06	Gruenenthal Gmbh	Derivados de ciclo-hexano espirocíclicos substituídos
WO2009118174A1 (de)	2008-03-27	2009-10-01	Grünenthal GmbH	Substituierte cyclohexyldiamine
CA2719735A1 (en)	2008-03-27	2009-10-01	Gruenenthal Gmbh	Substituted 4-aminocyclohexane derivatives
JP5599774B2 (ja) *	2008-03-27	2014-10-01	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	ヒドロキシメチルシクロヘキシルアミン類
EA019713B1 (ru)	2008-05-16	2014-05-30	Эли Лилли Энд Компани	ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt)	2008-07-08	2018-06-12	Intellikine Inc	compostos inibidores de quinase e métodos de uso
CA2738429C (en)	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
EP2358720B1 (en)	2008-10-16	2016-03-02	The Regents of The University of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
WO2010056309A2 (en) *	2008-11-14	2010-05-20	The Scripps Research Institute	Methods and compositions related to targeting monoacylglycerol lipase
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
WO2010138685A1 (en)	2009-05-27	2010-12-02	Ptc Therapeutics, Inc.	Methods for treating prostate conditions
MX373926B (es)	2009-05-27	2020-07-10	Ptc Therapeutics Inc	Metodos para tratar cancer y estados no neoplasicos.
WO2010138652A1 (en)	2009-05-27	2010-12-02	Ptc Therapeutics, Inc.	Methods for treating kaposi sarcoma
CA2763479A1 (en)	2009-05-27	2010-12-02	Ptc Therapeutics, Inc.	Processes for the preparation of substituted tetrahydro beta-carbolines
IN2012DN00352A (2)	2009-06-16	2015-08-21	Bikam Pharmaceuticals Inc
EP2459533A4 (en) *	2009-07-30	2013-01-16	Univ Singapore	SMALL MOLECULAR ISOPRENYLCYSTONE CARBOXYL METHYLTRANSFERASE HEMMER WITH POTENTIAL ANTIBODY EFFECT
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
MX2012004995A (es) *	2009-10-29	2012-10-03	Sirtris Pharmaceuticals Inc	Piridinas biciclicas y analogos como moduladores de sirtuina.
AU2011212813B2 (en)	2010-02-04	2014-10-23	Radius Health, Inc.	Selective androgen receptor modulators
HUE030072T2 (en)	2010-05-12	2017-04-28	Radius Health Inc	Therapeutic prescriptions
CA2799579A1 (en)	2010-05-21	2011-11-24	Intellikine, Inc.	Chemical compounds, compositions and methods for kinase modulation
WO2011155983A1 (en) *	2010-06-07	2011-12-15	Bikam Pharmaceuticals Inc.	Opsin-binding ligands, compositions and methods of use
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
US9133182B2 (en)	2010-09-28	2015-09-15	Radius Health, Inc.	Selective androgen receptor modulators
EP2625189B1 (en)	2010-10-01	2018-06-27	ModernaTX, Inc.	Engineered nucleic acids and methods of use thereof
JP2013545749A (ja)	2010-11-10	2013-12-26	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環化合物及びその使用
JP5951625B2 (ja)	2010-11-24	2016-07-13	ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅＴｒｕｓｔｅｅｓＯｆＣｏｌｕｍｂｉａＵｎｉｖｅｒｓｉｔｙＩｎＴｈｅＣｉｔｙＯｆＮｅｗＹｏｒｋ	加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト
GB201021103D0 (en)	2010-12-13	2011-01-26	Univ Leuven Kath	New compounds for the treatment of neurodegenerative diseases
ES2637113T3 (es)	2011-01-10	2017-10-10	Infinity Pharmaceuticals, Inc.	Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
EP2671589A4 (en) *	2011-02-02	2014-11-19	Public Univ Corp Nagoya City Univ	MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY
US9295673B2 (en)	2011-02-23	2016-03-29	Intellikine Llc	Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
WO2012127885A1 (ja)	2011-03-18	2012-09-27	小野薬品工業株式会社	テトラヒドロカルボリン誘導体
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
HK1198443A1 (en)	2011-07-19	2015-04-24	无限药品股份有限公司	Heterocyclic compounds and uses thereof
AR088218A1 (es)	2011-07-19	2014-05-21	Infinity Pharmaceuticals Inc	Compuestos heterociclicos utiles como inhibidores de pi3k
MX2014002542A (es)	2011-08-29	2014-07-09	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y usos de los mismos.
CA2846496C (en)	2011-09-02	2020-07-14	The Regents Of The University Of California	Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
CN103030643B (zh) *	2011-09-29	2015-04-29	中国科学院化学研究所	六环吲哚类生物碱及其制备方法
DE19216461T1 (de)	2011-10-03	2021-10-07	Modernatx, Inc.	Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
AR088377A1 (es)	2011-10-20	2014-05-28	Siena Biotech Spa	Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
EP2606726A1 (de)	2011-12-21	2013-06-26	Bayer CropScience AG	N-Arylamidine-substituierte trifluoroethylsulfid-Derivate als Akarizide und Insektizide
CN104411338A (zh)	2012-04-02	2015-03-11	现代治疗公司	用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US9333202B2 (en)	2012-05-01	2016-05-10	The Trustees Of Columbia University In The City Of New York	Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2690091A1 (en)	2012-07-25	2014-01-29	Studiengesellschaft Kohle mbH	Process for preparing substituted indole derivatives
EP2895462A1 (en) *	2012-09-13	2015-07-22	Baden-Württemberg Stiftung gGmbH	Specific inhibitors of protein p21 as therapeutic agents
JP2015532287A (ja)	2012-09-26	2015-11-09	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	Ｉｒｅ１の調節
AU2013337717B2 (en)	2012-11-01	2018-10-25	Infinity Pharmaceuticals, Inc.	Treatment of cancers using PI3 kinase isoform modulators
PL2922554T3 (pl)	2012-11-26	2022-06-20	Modernatx, Inc.	Na zmodyfikowany na końcach
WO2014152018A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	Octahydrocyclopentapyrroles, their preparation and use
EP3495357B1 (en)	2013-03-14	2021-05-05	The Trustees of Columbia University in the City of New York	4-phenylpiperidines, their preparation and use
US9938291B2 (en)	2013-03-14	2018-04-10	The Trustess Of Columbia University In The City Of New York	N-alkyl-2-phenoxyethanamines, their preparation and use
US9944644B2 (en)	2013-03-14	2018-04-17	The Trustees Of Columbia University In The City Of New York	Octahydropyrrolopyrroles their preparation and use
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
EP2986599A1 (en)	2013-04-17	2016-02-24	Pfizer Inc.	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US10561707B2 (en) *	2013-09-08	2020-02-18	Technion Research And Development Foundation Ltd.	Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
PT3052485T (pt)	2013-10-04	2021-10-22	Infinity Pharmaceuticals Inc	Compostos heterocíclicos e suas utilizações
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX382033B (es)	2014-03-19	2025-03-13	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
SG11201608303QA (en)	2014-04-04	2016-11-29	Del Mar Pharmaceuticals	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
SG11201608943VA (en)	2014-04-30	2016-11-29	Univ Columbia	Substituted 4-phenylpiperidines, their preparaiton and use
MX388871B (es)	2014-06-27	2025-03-20	Nogra Pharma Ltd	Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
EP3171895A1 (en)	2014-07-23	2017-05-31	Modernatx, Inc.	Modified polynucleotides for the production of intrabodies
WO2016014975A2 (en) *	2014-07-25	2016-01-28	Northeastern University	Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
BR112017004612A2 (pt) *	2014-09-10	2018-01-30	Epizyme, Inc.	compostos, composição farmacêutica, usos de um composto, e kit
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20170063954A (ko)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
WO2017007756A1 (en)	2015-07-06	2017-01-12	Rodin Therapeutics, Inc	Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (en)	2015-07-06	2018-05-16	Rodin Therapeutics, Inc.	Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017048702A1 (en)	2015-09-14	2017-03-23	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX389702B (es)	2016-06-22	2025-03-20	Ellipses Pharma Ltd	Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
SG11201811237WA (en)	2016-06-24	2019-01-30	Infinity Pharmaceuticals Inc	Combination therapies
US11168068B2 (en)	2016-07-18	2021-11-09	Janssen Pharmaceutica Nv	Tau PET imaging ligands
WO2018038188A1 (ja)	2016-08-26	2018-03-01	住友化学株式会社	フェニルウレア化合物及びその用途
US10893676B2 (en)	2016-08-26	2021-01-19	Sumitomo Chemical Company, Limited	1-acetyl-3-phenyl urea compound, and use thereof
US10040804B2 (en)	2016-12-21	2018-08-07	Biotheryx, Inc.	Compounds targeting proteins, compositions, methods, and uses thereof
HUE057849T2 (hu)	2017-01-11	2022-06-28	Alkermes Inc	Hiszton deacetiláz biciklusos gátlói
SG11201908351TA (en)	2017-03-10	2019-10-30	Edmond J Lavoie	Indole derivatives as efflux pump inhibitors
WO2018165612A1 (en)	2017-03-10	2018-09-13	Rutgers, The State University Of New Jersey	Bacterial efflux pump inhibitors
US11938114B2 (en)	2017-03-10	2024-03-26	Rutgers, The State University Of New Jersey	Bacterial efflux pump inhibitors
EP3630109A4 (en)	2017-05-26	2021-03-17	Rutgers, the State University of New Jersey	BACTERIAL EFFLUX PUMP INHIBITORS
MA49421A (fr)	2017-06-15	2020-04-22	Modernatx Inc	Formulations d'arn
WO2019005841A1 (en) *	2017-06-26	2019-01-03	Rutgers, The State University Of New Jersey	THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
EP3664803A4 (en)	2017-08-01	2021-05-05	PTC Therapeutics, Inc.	DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
LT3664802T (lt)	2017-08-07	2022-06-27	Alkermes, Inc.	Bicikliniai histonų deacetilazės inhibitoriai
EP3675817A1 (en)	2017-08-31	2020-07-08	Modernatx, Inc.	Methods of making lipid nanoparticles
US10882821B1 (en)	2017-09-26	2021-01-05	The Board Of Trustees Of The Leland Stanford Junior University	Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
JP7346425B2 (ja)	2018-01-11	2023-09-19	セントラスセラピューティクス	疾患を治療するためのジヒドロセラミドデサチュラーゼ阻害剤
WO2020061457A1 (en)	2018-09-20	2020-03-26	Modernatx, Inc.	Preparation of lipid nanoparticles and methods of administration thereof
EP4267578A4 (en)	2020-12-23	2024-11-20	Recurium IP Holdings, LLC	ESTROGEN RECEPTOR MODULATORS
CN118284598B (zh) *	2021-11-19	2025-06-24	杭州拿因生物科技有限责任公司	四氢咔唑类化合物、其药物组合物及用途
EP4711356A1 (en)	2023-05-10	2026-03-18	Nain Biotech (Hangzhou) Co., Ltd.	Tetrahydrocarbazole derivative, pharmaceutical composition, and use thereof
KR20260040871A (ko) *	2024-09-19	2026-03-26	이화여자대학교 산학협력단	피라지노 카바졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
EP4725481A1 (en) *	2024-10-10	2026-04-15	Leibniz-Institut für Virologie	1,2,3,4-tetrahydrocarbazole derivatives for use in treating an adenoviral infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1003577B (de) *	1955-02-11	1957-02-28	Agfa Ag	Verfahren zur Herstellung seitenrichtiger positiver Bilder durch Waermeentwicklung
BE793493A (fr)	1971-12-30	1973-06-29	Hoffmann La Roche	Composes tricycliques
BG25793A3 (bg)	1973-07-18	1978-12-12	Schering Aktiengesellschaft	Метод за получаване на карбазолови деривати
US4014890A (en) *	1976-03-23	1977-03-29	Pfizer Inc.	Process for preparing indole derivatives
DE3217563A1 (de)	1982-05-11	1983-11-17	Cassella Ag, 6000 Frankfurt	Verfahren zur herstellung gegebenenfalls substituierter 1,2,3,4-tetrahydro-9-cyanmethyl-carbazol-1-one
US4880817A (en) *	1987-06-09	1989-11-14	Ortho Pharmaceutical Corporation	O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US5166204A (en) *	1989-11-01	1992-11-24	Toyama Chemical Co., Ltd.	Isoindole derivatives and salts thereof and antitumor agent comprising the same
US5192789A (en)	1991-01-18	1993-03-09	Hoechst-Roussel Pharmaceuticals Incorporated	Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[b]indoles and related compounds
US5100891A (en)	1991-01-18	1992-03-31	Hoechst-Roussel Pharmaceuticals Inc.	Substituted 1,2,3,4-tetrahydrocyclopent[b]indoles, 1,2,3,3a,4,8a-hexahydrocyclopent[B]indoles and related compounds
US5298626A (en)	1991-01-18	1994-03-29	Hoechst-Roussel Pharmaceuticals Incorporated	Select cyclopent[b]indoles
US5451600A (en) *	1994-04-19	1995-09-19	Hoffmann-La Roche Inc.	Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors
US5892041A (en) *	1996-08-12	1999-04-06	Neurogen Corporation	Fused indolecarboxamides: dopamine receptor subtype specific ligands
FR2763589B1 (fr)	1997-05-22	2001-01-05	Centre Nat Rech Scient	Composes pour la preparation de medicaments destines au traitement de pathologies impliquant le glutamate extracellulaire, et leurs procedes d'obtention
AR016133A1 (es) *	1997-07-31	2001-06-20	Wyeth Corp	Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6514981B1 (en) *	1998-04-02	2003-02-04	Sugen, Inc.	Methods of modulating tyrosine protein kinase function with indolinone compounds
GB9918962D0 (en)	1999-08-11	1999-10-13	Cerebrus Ltd	Chemical compounds xxii
ES2288871T3 (es) *	1999-09-24	2008-02-01	Genentech, Inc.	Derivados de tirosina.
DE19962936A1 (de)	1999-12-24	2001-06-28	Bayer Ag	Neue beta-Aminosäureverbindungen als Integrinantagonisten
EP1458374A2 (en)	2001-12-14	2004-09-22	Novo Nordisk A/S	Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
US20040023961A1 (en) *	2002-02-11	2004-02-05	Bayer Corporation	Aryl ureas with raf kinase and angiogenisis inhibiting activity
CA2488363C (en)	2002-06-06	2011-01-04	Institute Of Medicinal Molecular Design, Inc.	O-substituted hydroxyaryl derivatives
US20060004029A1 (en) *	2002-08-30	2006-01-05	Akihiko Tsuruoka	Nitrogen-containing aromatic derivatives
EA010267B1 (ru) *	2002-10-07	2008-06-30	Те Риджентс Оф Те Юниверсити Оф Калифорния	Модуляция тревоги через блокаду гидролиза анандамида
US7622592B2 (en) *	2002-11-01	2009-11-24	Merck & Co., Inc.	Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004069831A1 (en) *	2003-02-10	2004-08-19	Glenmark Pharmaceuticals Ltd.	Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation
EP1599202A1 (en) *	2003-02-17	2005-11-30	Pharmacia Italia S.p.A.	Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003902023A0 (en) *	2003-04-29	2003-05-15	The Australian National University	A method of indole synthesis
ES2314446T3 (es)	2003-06-10	2009-03-16	Smithkline Beecham Corporation	Derivados de tetrahidrocarbazol y su uso farmaceutico.
RU2005138126A (ru) *	2003-06-12	2006-07-27	СмитКлайн Бичем Корпорейшн (US)	Производные тетрагидрокарбазола и их фармацевтическое применение
US7605166B2 (en) *	2003-06-25	2009-10-20	Elan Pharmaceuticals Inc.	Methods and compositions for treating rheumatoid arthritis
EP1677794B1 (en)	2003-09-12	2014-12-03	Elixir Pharmaceuticals, Inc.	Methods of treating disorder
JP2007509057A (ja)	2003-10-15	2007-04-12	カイロンコーポレイション	ウイルス阻害のための組成物および方法
WO2005097162A2 (en) *	2004-04-01	2005-10-20	Elan Pharmaceuticals, Inc.	Steroid sparing agents and their use
CA2563432A1 (en)	2004-04-16	2005-12-01	Genentech, Inc.	Method for augmenting b cell depletion

2005
- 2005-11-23 WO PCT/US2005/042484 patent/WO2006058088A2/en not_active Ceased
- 2005-11-23 JP JP2007543448A patent/JP2008520740A/ja active Pending
- 2005-11-23 WO PCT/US2005/042483 patent/WO2006065480A2/en not_active Ceased
- 2005-11-23 EP EP05852076A patent/EP1824821A2/en not_active Withdrawn
- 2005-11-23 MX MX2007006180A patent/MX2007006180A/es not_active Application Discontinuation
- 2005-11-23 WO PCT/US2005/042482 patent/WO2006065479A2/en not_active Ceased
- 2005-11-23 US US11/720,055 patent/US8946444B2/en not_active Expired - Fee Related
- 2005-11-23 MX MX2007006178A patent/MX2007006178A/es not_active Application Discontinuation
- 2005-11-23 JP JP2007543450A patent/JP2008520742A/ja active Pending
- 2005-11-23 MX MX2007006179A patent/MX2007006179A/es not_active Application Discontinuation
- 2005-11-23 EP EP05852075A patent/EP1817025A2/en not_active Withdrawn
- 2005-11-23 CA CA002588389A patent/CA2588389A1/en not_active Abandoned
- 2005-11-23 US US11/720,061 patent/US8143257B2/en not_active Expired - Fee Related
- 2005-11-23 CA CA002588607A patent/CA2588607A1/en not_active Abandoned
- 2005-11-23 CA CA002588384A patent/CA2588384A1/en not_active Abandoned
- 2005-11-23 EP EP05852074A patent/EP1828195A2/en not_active Withdrawn
- 2005-11-23 JP JP2007543449A patent/JP2008520741A/ja active Pending
2015
- 2015-01-26 US US14/605,721 patent/US9271960B2/en not_active Expired - Lifetime

Publication	Publication Date	Title
JP2008520742A5 (2)	2009-03-05
CN111225896B (zh)	2024-03-26	免疫调节剂化合物
DE60122175T2 (de)	2007-07-05	Chemokinrezeptor bindende heterozyklische Verbindungen
JP2012530765A5 (2)	2013-08-08
CA3142069A1 (en)	2021-01-21	Aurora kinase inhibitor and use thereof
JP2018511590A5 (2)	2019-04-18
JP2011504903A5 (2)	2013-10-03
RU2012151012A (ru)	2014-06-10	Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием
JP2014503574A5 (2)	2015-02-26
JP2011515462A5 (2)	2012-05-17
JP5167241B2 (ja)	2013-03-21	癌の処置用のヒストンデアセチラーゼ阻害剤としての、ｎ−ヒドロキシ−３−（４−｛３−フェニル−ｓ−オキソ−プロペニル｝−フェニル）−アクリルアミド誘導体及びその関連化合物
JP2012510502A5 (2)	2013-01-24
JP2005514420A5 (2)	2005-12-22
JP2017508733A5 (2)	2021-01-21
US11001581B2 (en)	2021-05-11	Compounds which inhibit RNA polymerase, compositions including such compounds, and their use
JP2009532417A5 (2)	2010-06-03
JP2011512412A5 (2)	2012-03-22
JP2013500342A5 (2)	2013-09-12
WO2014200075A1 (ja)	2014-12-18	４－アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬
JP2010506919A5 (2)	2012-07-12
JP2012524107A5 (2)	2013-05-30
JP2007532627A5 (2)	2008-05-22
JP2010526801A5 (2)	2010-09-24
JP2009501745A5 (2)	2009-09-10
RU2006130686A (ru)	2008-03-10	Новые пиперидины в качестве модуляторов хемокинов (ccr)